Co-stimulatory Receptors

Cat. No.

AT0141

CAS No.

2055640-86-1

Mitazalimab

Synonyms: ADC-1013; JNJ-64457107

Mitazalimab (ADC-1013; JNJ-64457107) functions as an FcγR-dependent CD40 agonist, specifically designed to exhibit tumor-directed activity. This therapeutic agent effectively activates antigen-presenting cells, such as dendritic cells (DCs), thereby initiating the activation of tumor-reactive T cells. Consequently, Mitazalimab promotes the infiltration and activation of tumor-specific T cells, which are instrumental in targeting and destroying tumor cells. Additionally, this compound plays a crucial role in remodeling the tumor-infiltrating myeloid microenvironment, enhancing its therapeutic efficacy against cancerous tissues.

Cat. No.

AT0266

ADG-106

ADG-106 is a fully human agonistic monoclonal IgG4 antibody targeting CD137 (4-1BB). This antibody is designed to activate CD137 through potent FcγRIIB-mediated crosslinking, concurrently antagonizing CD137 ligands. For isotype control purposes, Human IgG4 (S228P) kappa, Isotype Control is recommended. This product is pivotal in studies focused on the modulation of immune responses, particularly in the context of immunotherapy and cancer research.

Cat. No.

AT0328

CAS No.

1622140-49-1

Selicrelumab

Selicrelumab is an agonistic antibody targeting CD40, known to modulate the tumor microenvironment significantly. This antibody is specifically designed for use in research focused on pancreatic cancer and neoadjuvant therapies. Selicrelumab facilitates the study of CD40's role in oncologic pathways and immune responses, making it a valuable tool for advancing cancer treatment modalities.

Cat. No.

AT0329

CAS No.

2444297-08-7

Boserolimab

Synonyms: MK-5890

Boserolimab (MK-5890) is a humanized agonist monoclonal antibody designed to target CD27. By binding to CD27, it delivers a costimulatory signal that significantly enhances T-cell-mediated immune responses. This antibody is pivotal for research focused on immunotherapy and the modulation of immune responses in various diseases.

Cat. No.

AT0610

CAS No.

1629760-27-5

Cifurtilimab

Synonyms: SEA-CD40

Cifurtilimab (SEA-CD40) is an agonistic, non-fucosylated human IgG1 monoclonal antibody that targets CD40, a co-stimulatory protein found on antigen-presenting cells. This antibody has been engineered to enhance immune activation and exhibits significant antitumor activities, making it a valuable tool for research in cancer immunotherapy.

Cat. No.

AT0633

CAS No.

2230138-89-1

Revdofilimab

Synonyms: ABBV-368

Revdofilimab (ABBV-368) is a human IgG1 monoclonal antibody designed as an agonist targeting OX40, a constituent of the TNF receptor superfamily. OX40 is predominantly expressed on subsets of activated and memory T cells as well as T regulatory cells. This antibody facilitates the modulation of immune responses, making it a valuable tool in immunological research and therapeutic development.

Cat. No.

AT0659

CAS No.

2226292-20-0

Giloralimab

Synonyms: ABBV-927

Giloralimab (ABBV-927) is a potent agonistic monoclonal antibody targeting CD40. This antibody is designed to modulate immune responses, making it a valuable tool for cancer research. Its agonistic properties can potentially enhance anti-tumor immunity, providing a promising approach for investigational studies in oncology.

Cat. No.

AT0825

MK-4166

MK-4166 is a humanized IgG1 monoclonal antibody designed as an agonist targeting the glucocorticoid-induced TNFR-related protein (GITR). This antibody facilitates the enhancement of proliferation in both naïve and tumor-infiltrating T lymphocytes, making it a critical tool in the study of T cell dynamics and cancer immunotherapy. MK-4166's specificity for GITR and its agonistic properties position it as a valuable agent for research focused on immune response modulation within oncological environments.

Cat. No.

AT0878

CAS No.

2252518-85-5

Feladilimab

Synonyms: Anti-ICOS/CD278 Reference Antibody (feladilimab; GSK3359609

Feladilimab (GSK3359609) is a humanized IgG4 monoclonal antibody that functions as an agonist targeting ICOS (CD278). This antibody selectively binds to ICOS-expressing T cells, a critical interaction in the modulation of immune responses. Due to its mechanism of action, Feladilimab is primarily investigated for its potential applications in cancer research, where it may influence T cell activity and tumor immune evasion.

Cat. No.

AT0906

CAS No.

1638935-72-4

Vonlerolizumab

Synonyms: Pogalizumab; MOXR 0916

Vonlerolizumab (MOXR 0916) is a humanized IgG monoclonal antibody that functions as an agonist targeting the OX40 receptor. This antibody is specifically designed for the study of cancer immunotherapy, facilitating research into the modulation of T-cell activity and the enhancement of anti-tumor immune responses.

Cat. No.

AT1089

CAS No.

934823-49-1

Urelumab

Urelumab is a fully human IgG4 monoclonal antibody that functions as a CD137 agonist without binding to its natural ligand. This antibody is designed to potentiate the antitumor activities of T-cells and natural killer (NK) cells. Additionally, Urelumab has been shown to potentially enhance the cytotoxic effects of Rituximab. It is primarily utilized in research focused on various non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma. This makes Urelumab a valuable tool in the study of immune-mediated cancer therapies.

Cat. No.

AT1298

CAS No.

2305607-45-6

Sotigalimab

Sotigalimab is a CD40 agonistic monoclonal antibody designed to selectively bind to CD40 with high affinity. This interaction promotes the activation of antigen-presenting cells, which in turn enhances cancer-specific T cell responses. Primarily utilized in research focused on metastatic pancreatic cancer and metastatic melanoma, Sotigalimab serves as a critical tool in the investigation of immune-mediated therapies targeting these aggressive cancers.

Cat. No.

AT1357

CAS No.

2207590-51-8

Ragifilimab

Synonyms: INCAGN-1876

Ragifilimab (INCAGN-1876) is an agonistic monoclonal antibody designed to specifically target the glucocorticoid-induced TNFR-related protein (GITR). This antibody has been developed for use in research involving advanced or metastatic solid tumors, exploring its potential to modulate immune responses and enhance anti-tumor activity. Ragifilimab provides a valuable tool for investigating the therapeutic implications of GITR activation in oncological studies.

Cat. No.

AT1360

CAS No.

2089398-68-3

GSK-3174998

GSK-3174998 is a humanized IgG1 monoclonal antibody that functions as an agonist to OX40 (TNFRSF4), a member of the TNF receptor superfamily. This antibody is designed to selectively bind to OX40, enhancing the immune response against cancer cells. It holds significant potential for research into the treatment of advanced solid tumors. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT1393

CAS No.

1417318-27-4

Utomilumab

Synonyms: PF 05082566

Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody designed for selective binding to 4-1BB/CD137, a costimulatory receptor involved in the regulation of immune cell activation and survival. This antibody has potential applications in oncology research, particularly in the study of follicular and other CD20+ non-Hodgkin lymphomas, where it may enhance antitumor immune responses.

Cat. No.

AT1437

CAS No.

2039148-04-2

Vopratelimab

Synonyms: JTX 2011

Vopratelimab (JTX-2011) is a humanized IgG1-kappa agonist monoclonal antibody designed to selectively target the Inducible T-cell CO-Stimulator (ICOS), a critical molecule in the modulation of T-cell activity. This antibody exhibits strong species cross-reactivity, demonstrating binding affinities of 0.93 nM for human ICOS, 0.46 nM for cynomolgus ICOS, 3.7 nM for rat ICOS, and 0.64 nM for murine ICOS. Vopratelimab is primarily utilized in research focused on enhancing antitumor immune responses, making it a valuable tool in oncology and immunotherapy studies.

Cat. No.

AT1475

CAS No.

906068-56-2

Theralizumab

Synonyms: TGN1412

Theralizumab (TGN1412) is a humanized IgG4 monoclonal antibody with superagonistic properties targeting CD28. It directly stimulates T-cell activation, which can lead to cytokine release syndrome (CRS). This antibody is primarily utilized in research focused on understanding and potentially treating rheumatoid arthritis.

Cat. No.

AT1528

CAS No.

2128729-41-7

Ivuxolimab

Ivuxolimab is a monoclonal antibody that acts as an agonist to OX40, also identified as CD134 or TNFRSF4. This costimulatory receptor is predominantly expressed on activated CD4+ and CD8+ T cells. The antibody is designed to enhance immune responses and has demonstrated significant antitumor activity, suggesting its utility in immunotherapy applications.